Effectiveness of sacubitril–valsartan in cancer patients with heart failure

AIMS: Current guidelines recommend sacubitril/valsartan for patients with heart failure and reduced left ventricular ejection fraction (LVEF), but there is lack of evidence of its efficacy and safety in cancer therapy‐related cardiac dysfunction (CTRCD). Our aim was to analyse the potential benefit...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:ESC Heart Fail
Main Authors: Martín‐Garcia, Ana, López‐Fernández, Teresa, Mitroi, Cristina, Chaparro‐Muñoz, Marinela, Moliner, Pedro, Martin‐Garcia, Agustin C., Martinez‐Monzonis, Amparo, Castro, Antonio, Lopez‐Sendon, Jose L., Sanchez, Pedro L.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Short Communications
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7160493/
https://ncbi.nlm.nih.gov/pubmed/32022485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12627
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki